Modality
Vaccine
MOA
TYK2i
Target
IL-17A
Pathway
STING
Alzheimer's
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
~Aug 2023
→ ~Nov 2024
Phase 2
Feb 2025
→ Mar 2030
Phase 2Current
NCT03030186
1,126 pts·Alzheimer's
2025-02→2030-03·Not yet recruiting
1,126 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-103.9y awayPh3 Readout· Alzheimer's
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2030-03-10 · 3.9y away
Alzheimer's
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03030186 | Phase 2/3 | Alzheimer's | Not yet recr... | 1126 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |